2.2 Pharmacokinetic Schedule
Iberdomide PK data was collected for all three studies. All available PK
data from CP-001, Part 1(multiple ascending dose; Table 1) and 3
(relative bioavailability; Table 1) from CP-002 and cohorts A
(iberdomide monotherapy dose escalation; Table 1), B (iberdomide in
combination with DEX dose escalation; Table 1), D (iberdomide in
combination with DEX dose expansion; Table 1), E (iberdomide in
combination with DARA and DEX dose escalation; Table 1),) and I
(iberdomide in combination with DEX dose expansion; Table 1) from MM-001
studies were included in the popPK analysis, based upon the relevance to
this analysis. M12 PK data was only collected in CC-220-MM-001 Cohorts
A, B and E. The sampling schedule of M12 is similar as iberdomide.
The PK sampling schedule was detailed in Table 1.